A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501) in Women - Full Text View

Sponsor:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00090220

Purpose

This study is to assess the tolerability and efficacy of a vaccine being evaluated to reduce the incidence of human papillomavirus (HPV) infection and disease (external genital warts and vulvar, vaginal, and cervical cancer) in women.

Condition	Intervention	Phase
Healthy Papillomavirus Infection	Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine Biological: Comparator: Placebo	Phase III

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study

Resource links provided by NLM:

MedlinePlus related topics: Cancer Genital Warts Warts

U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:

Combined incidence of HPV6/11/16/18 related persistent infection, genital warts, VIN, VaIN, vulvar cancer, vaginal cancer, cervical dysplasia, cervical AIS, and cervical cancer [ Time Frame: 48 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Combined incidence of HPV6/11 related persistent infection, genital warts, VIN, VaIN, vulvar cancer, vaginal cancer, cervical dysplasia, cervical AIS, and cervical cancer [ Time Frame: 48 months ] [ Designated as safety issue: No ]

Enrollment:	3800
Study Start Date:	June 2004
Estimated Study Completion Date:	March 2011
Primary Completion Date:	July 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Gardasil	Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine Gardasil intramuscular injection in three 0.5 mL doses over 6 months.
2: Placebo Comparator Placebo	Biological: Comparator: Placebo Placebo intramuscular injection in three 0.5 mL doses over 6 months.

Eligibility

Ages Eligible for Study:	24 Years to 45 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

No history of HPV infection, surgical treatment to the cervix, or genital warts

Exclusion Criteria:

Subject is pregnant
Subject previously received any HPV vaccine

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00090220

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

Publications:

Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009 Jun 6;373(9679):1949-57. Epub 2009 Jun 1.

Velicer C, Zhu X, Vuocolo S, Liaw KL, Saah A. Prevalence and Incidence of HPV Genital Infection in Women. Sex Transm Dis. 2009 Jul 31; [Epub ahead of print]

Responsible Party:	Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences )
Study ID Numbers:	2004_013, V501-019
Study First Received:	August 25, 2004
Last Updated:	October 29, 2009
ClinicalTrials.gov Identifier:	NCT00090220 History of Changes
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Virus Diseases
Tumor Virus Infections
DNA Virus Infections
Papillomavirus Infections
Infection

ClinicalTrials.gov processed this record on November 22, 2009